AMCP Applauds Introduction of the Access to Prescription Digital Therapeutics Act of 2025

Legislation will help expand patient access to a growing, promising line of health technology-enabled treatments.

Alexandria, VA., May 8, 2025  — AMCP (Academy of Managed Care Pharmacy) today applauded the introduction of the Access to Prescription Digital Therapeutics Act of 2025 (S. 1702/H.R. 3288) by Senators Shelley Moore Capito (R-WV) and Jeanne Shaheen (D-NH)) and Representatives Kevin Hern (R-OK) and Mike Thompson (D-CA). AMCP has long championed this legislation that would authorize coverage of prescription digital therapeutics (PDTs) by Medicare and Medicaid, helping millions of Americans receive innovative care to treat a growing range of conditions and illnesses.

“Prescription digital therapeutics offer some of the most innovative, promising treatments coming to market and this bill will help pave the way for millions of Medicare beneficiaries to have access to potentially life-saving care,” said AMCP CEO Susan Cantrell, MHL, RPh, CAE. “AMCP has been a leading advocate for authorizing coverage of PDTs so we can level the playing field to help Medicare beneficiaries, and we ask Congress to support this important legislation aimed at improving healthcare outcomes for seniors and other vulnerable populations.”

PDTs are evidence-based treatments that use software or virtual tools, and sometimes hardware, to deliver a clinical benefit to patients. They have many known uses, helping Americans identify, treat, and manage illnesses across a wide range of conditions, including post-traumatic stress disorder (PTSD), diabetes management, substance and opioid use disorder, attention-deficit hyperactivity disorder (ADHD), chronic back pain, decreasing eyesight, and more. PDTs are subject to review and authorization by the Food & Drug Administration (FDA) and must be prescribed by a health care provider.

The current version of the bill is identical to language from the 118th Congress, apart from new implementation dates.

Take action to urge Congress to pass this important bill. For more information on PDTs and AMCP’s support for this legislation, please view our Legislative & Regulatory Issues page.  

For media inquiries, contact AMCP.
 

About AMCP 

AMCP is the professional association leading the way to help patients get the medications they need at a cost they can afford. AMCP’s diverse membership of pharmacists, physicians, nurses, biopharmaceutical professionals, and other stakeholders leverage their specialized expertise in clinical evidence and economics to optimize medication benefit design and population health management and help patients access cost-effective and safe medications and other drug therapies. AMCP members improve the lives of nearly 300 million Americans served by private and public health plans, pharmacy benefit management firms, and emerging care models. Visit www.amcp.org.